BioXcel Therapeutics, Inc. (BTAI) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-12

Key Insights

The reporting person, David J. Mack, a director of BioXcel Therapeutics, Inc. (BTAI), acquired 17,000 stock options with an exercise price of $2.01 per share on January 9, 2026, which will vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting of shareholders.
This insider transaction indicates Mack's continued commitment and confidence in the company's future prospects, as he has increased his direct ownership stake in BTAI.
The timing of the option grant, which occurs shortly before the next annual meeting, suggests it may be part of the company's director compensation program and aligns Mack's interests with those of other shareholders.

Want the newest filings?

This analysis covers the filing from 2026-01-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-12

Insider June Bray, a director at BioXcel Therapeutics, acquired 17,000 stock options with an exercise price of $2.01 and a 10-year term.
The stock options will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Bray's continued service as a director.
This transaction suggests that an insider with knowledge of the company's operations believes the stock is undervalued and has confidence in the company's future performance.

Filed: 2026-01-12

Michael Patrick Miller, a director of BioXcel Therapeutics, Inc. (BTAI), has been granted a stock option to purchase 17,000 shares of the company's common stock at an exercise price of $2.01 per share.
The option vests on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Miller's continued service as a non-employee director.
This transaction represents an insider purchase and could signal Miller's confidence in the company's future prospects.

Filed: 2026-01-12

Michal Votruba, a director of BioXcel Therapeutics, Inc. (BTAI), acquired 17,000 stock options on January 9, 2026 with an exercise price of $2.01 and a 10-year expiration date.
The options vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Votruba's continued service as a non-employee director.
Insider purchases, especially by directors, can signal confidence in the company's prospects and potential future stock price appreciation.

Filed: 2026-01-12

The reporting person, Peter Mueller, has been granted a stock option to acquire 17,000 shares of BioXcel Therapeutics, Inc. (BTAI) common stock, with an exercise price of $2.01 and a 10-year expiration date.
The stock option will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to the reporting person's continued service as a non-employee director.
This transaction represents an insider's acquisition of equity in the company, which could signal their confidence in the company's future performance.

Filed: 2026-01-12

Rajiv Patni, a director of BioXcel Therapeutics, Inc., has acquired 17,000 stock options with an exercise price of $2.01 and a 10-year expiration date.
The options will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Patni's continued service as a non-employee director.
This insider transaction could signal Patni's confidence in the company's long-term prospects and alignment with shareholder interests.

Filed: 2026-01-12

Sandeep Laumas, a director of BioXcel Therapeutics, Inc. (BTAI), has been granted a stock option to purchase 17,000 shares of the company's common stock.
The stock option has a strike price of $2.01 and will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Laumas' continued service as a non-employee director.
This option grant suggests the company is compensating its directors to align their interests with those of shareholders and support the company's long-term growth.

Other reports for BioXcel Therapeutics, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.